Dr. Hönle AG revised earnings guidance for the year 2021/2022. The Management Board therefore expects sales of EUR 125 million to EUR 130 million and an operating loss (LBIT) of EUR 3 million to EUR 4 million for the Hönle Group in the 2021/2022 financial year. To date, the Executive Board has been expecting sales of between EUR 125 million and EUR 130 million (PY: EUR 115 million) and an operating result (EBIT) of between EUR 9 million and EUR 11 million (PY: EUR 0.3 million).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.8 EUR | -0.50% | -0.50% | +13.71% |
Feb. 26 | Dr. Hönle AG Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
Jan. 25 | Dr. Hönle AG Reports Earnings Results for the Full Year Ended September 30, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+13.71% | 129M | |
+12.39% | 82.35B | |
+20.17% | 71.09B | |
+20.89% | 37.73B | |
+15.77% | 32.01B | |
+9.19% | 27.2B | |
+3.18% | 26.74B | |
+4.22% | 26B | |
+13.38% | 25.5B | |
+17.14% | 24.76B |
- Stock Market
- Equities
- HNL Stock
- News Dr. Hönle AG
- Dr. Hönle AG Revises Earnings Guidance for the Year 2021/2022